Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the penny stocks with the potential to rise 1000 percent.
On March 27, Rocket Pharmaceuticals said the FDA approved KRESLADI for a rare pediatric disorder, giving the company its first marketed product and a key regulatory win after a long review path. The company said the approval also makes KRESLADI the first FDA-approved gene therapy for this condition, which gives Rocket a commercial foothold in an ultra-rare disease market.
The bigger takeaway is what came with the approval. Rocket said it also received a Rare Pediatric Disease Priority Review Voucher, an asset biotech companies can monetize, and management said it is evaluating strategic options for the voucher to enhance financial flexibility. The company added that it plans to make KRESLADI available to eligible U.S. patients.
Rocket has also been signaling a measured launch rather than a broad commercial push. Recent company disclosures described a scaled commercial effort tailored to the very small patient population, while Reuters reported the rollout is expected to begin through a limited number of specialized centers. As of December 31, 2025, Rocket had $188.9 million in cash, cash equivalents, and investments.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a biotechnology company focused on genetic therapies for rare disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.
While we acknowledge the potential of RCKT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
